Paul Juang

872 total citations
24 papers, 454 citations indexed

About

Paul Juang is a scholar working on Epidemiology, Infectious Diseases and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Paul Juang has authored 24 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 9 papers in Infectious Diseases and 6 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Paul Juang's work include Nosocomial Infections in ICU (5 papers), Pneumonia and Respiratory Infections (4 papers) and Antibiotic Use and Resistance (4 papers). Paul Juang is often cited by papers focused on Nosocomial Infections in ICU (5 papers), Pneumonia and Respiratory Infections (4 papers) and Antibiotic Use and Resistance (4 papers). Paul Juang collaborates with scholars based in United States, Germany and Canada. Paul Juang's co-authors include Marin H. Kollef, Scott T. Micek, Susan J. Skledar, William D. Shannon, David L. Paterson, Robert A. Branch, Nicholas Hampton, Nicole T. Ansani, Nathalie K. Zgheib and Emanuel N. Vergis and has published in prestigious journals such as SHILAP Revista de lepidopterología, Critical Care Medicine and Critical Care.

In The Last Decade

Paul Juang

22 papers receiving 442 citations

Peers

Countries citing papers authored by Paul Juang

Since Specialization

Citations

This map shows the geographic impact of Paul Juang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Juang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Juang more than expected).

Fields of papers citing papers by Paul Juang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Juang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Juang. The network helps show where Paul Juang may publish in the future.

Co-authorship network of co-authors of Paul Juang

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Juang. A scholar is included among the top collaborators of Paul Juang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Juang. Paul Juang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study 2021 ·Clinical Therapeutics ·Kevin D. Betthauser, (unknown), Paul Juang, Bryan Lizza, Scott T. Micek, Marin H. Kollef	0
2	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia 2019 ·Clinical Therapeutics ·(unknown), Paul Juang, (unknown), Marin H. Kollef, Kevin D. Betthauser	6
3	619: OUTCOMES OF MACROLIDE DE-ESCALATION IN SEVERE COMMUNITY- ACQUIRED PNEUMONIA 2019 ·Critical Care Medicine ·(unknown), Paul Juang, (unknown), Marin Kollef, Kevin D. Betthauser	0
4	A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure 2017 ·Surgical Infections ·Kristen Fisher, (unknown), Scott T. Micek, Paul Juang, Marin H. Kollef	9
5	Perceived Motivating Factors and Barriers for the Completion of Postgraduate Training Among American Pharmacy Students Prior to Beginning Advanced Pharmacy Practice Experiences 2017 ·American Journal of Pharmaceutical Education ·Drayton A. Hammond, Douglas R. Oyler, John W. Devlin, Jacob T. Painter, Scott Bolesta, Joseph M. Swanson, (unknown), (unknown), Jeffrey F. Barletta, (unknown), (unknown), Paul Juang, Sandra L. Kane‐Gill, Tyree H. Kiser, (unknown), Debra J. Skaar, Pamela L. Smithburger, (unknown)	28
6	Design and Validation of Patient-Centered Communication Tools (PaCT) to Measure Students’ Communication Skills 2017 ·American Journal of Pharmaceutical Education ·Gloria R. Grice, (unknown), (unknown), (unknown), (unknown), (unknown), Tricia M. Berry, (unknown), Janelle Mann, Paul Juang	27
7	Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study 2017 ·Critical Care ·(unknown), Kristen Fisher, Scott T. Micek, Paul Juang, Marin H. Kollef	21
8	Controversies and advances in the management of ventilator associated pneumonia 2017 ·Expert Review of Respiratory Medicine ·Katherine L. Roberts, Scott T. Micek, Paul Juang, Marin H. Kollef	12
9	Em08red, a dual functional antiproliferative emodin analogue, is a downregulator of ErbB2 expression and inducer of intracellular oxidative stress 2015 ·Drug Design Development and Therapy ·Paul Juang, (unknown), (unknown), (unknown), Chien‐Shu Chen	3
10	Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study 2014 ·Clinical Therapeutics ·Scott T. Micek, Heather Arnold, Paul Juang, Nicholas Hampton, Matthew McKenzie, (unknown), Marin H. Kollef	11
11	Role of Fidaxomicin for the Treatment of Clostridium difficile Infection 2013 ·Journal of Pharmacy Practice ·Paul Juang, (unknown)	4
12	Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study 2013 ·Annals of Pharmacotherapy ·Heather Arnold, James M. Hollands, Lee P. Skrupky, Jennifer R. Smith, Paul Juang, Nicholas Hampton, (unknown), Richard M. Reichley, (unknown), (unknown), Scott T. Micek, Marin H. Kollef	41
13	The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment* 2012 ·Critical Care Medicine ·Andrew Labelle, Paul Juang, Richard M. Reichley, Scott T. Micek, (unknown), (unknown), Nicholas Hampton, Marin H. Kollef	59
14	Fidaxomicin: A Macrocyclic Antibiotic for the Treatment of Clostridium difficile Infection 2011 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Paul Juang	23
15	Recurrent Ochrobactrum anthropi, Treatment, and Clinical Relevance 2010 ·Infectious Diseases in Clinical Practice ·(unknown), Paul Juang	6
16	Administering Intravenous Immune Globulin for a Patient With Clostridium difficile Infection and Acute Renal Failure 2010 ·Infectious Diseases in Clinical Practice ·(unknown), Paul Juang	1
17	Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea 2007 ·American Journal of Infection Control ·Paul Juang, Susan J. Skledar, Nathalie K. Zgheib, David L. Paterson, Emanuel N. Vergis, William D. Shannon, Nicole T. Ansani, Robert A. Branch	113
18	Update on New Antifungal Therapy 2007 ·AACN Advanced Critical Care ·Paul Juang	3
19	A Successful Rapid Desensitization Protocol in a Loop Diuretic Allergic Patient 2005 ·Journal of Cardiac Failure ·Paul Juang, Robert L. Page, Ronald Zolty	5
20	Probable Loop Diuretic–Induced Pancreatitis in a Sulfonamide-Allergic Patient 2005 ·Annals of Pharmacotherapy ·Paul Juang, Robert L. Page, Ronald Zolty	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact